Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningPeripheral Blood Stem Cell TransplantationHematopoietic Stem CellsTransplantation, AutologousHematologic NeoplasmsStem Cell TransplantationTransplantation ChimeraTissue DonorsBone MarrowWhole-Body IrradiationGraft vs Leukemia EffectBusulfanBone Marrow CellsTreatment OutcomeLeukemiaHistocompatibilityGraft SurvivalHistocompatibility TestingRecurrenceMyeloablative AgonistsStem CellsHematopoietic Stem Cell MobilizationGraft vs Tumor EffectRetrospective StudiesChimerismLeukemia, Myeloid, AcuteHematologic DiseasesAnemia, AplasticCord Blood Stem Cell TransplantationRemission InductionCombined Modality TherapyVidarabineImmunosuppressive AgentsMyelodysplastic SyndromesCyclophosphamideLymphocyte TransfusionHLA AntigensPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation, IsogeneicHematopoiesisAntigens, CD34Hepatic Veno-Occlusive DiseaseTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAllograftsSurvival RateSiblingsSurvival AnalysisGranulocyte Colony-Stimulating FactorCytomegalovirus InfectionsTransplantation ImmunologyAcute DiseaseLiver TransplantationT-LymphocytesMultiple MyelomaLymphocyte DepletionDisease-Free SurvivalFlow CytometryAntineoplastic Combined Chemotherapy ProtocolsMice, Inbred C57BLFollow-Up StudiesMelphalanSevere Combined ImmunodeficiencyOpportunistic InfectionsLeukapheresisSalvage TherapyNeoplasm, ResidualLeukemia, MyeloidImmunosuppressionAntilymphocyte SerumCystitisMinor Histocompatibility AntigensLeukemic InfiltrationBone Marrow PurgingKidney TransplantationLymphoproliferative DisordersCell DifferentiationLymphoma, Non-HodgkinCytarabineBlood Group IncompatibilityFatal OutcomeCytomegalovirusGraft RejectionPrognosisBone and BonesCyclosporineColony-Forming Units AssayImmunocompromised HostRisk FactorsBone Marrow DiseasesBlood Component RemovalCells, CulturedBronchiolitis ObliteransBlood CellsFetal BloodMesenchymal Stem Cell Transplantation